Peptide Laboratory Practice
BPC-157 and TB-500 Blend COA Testing Guide
Audit BPC-157 and TB-500 blend COAs with component-specific LC-MS, calibrated ratio testing, sequence disclosure, final-vial assay, and carryover controls.
A BPC-157 plus TB-500 blend cannot be released from two single-peptide COAs stapled together. Those certificates may qualify the starting materials. They do not prove that the final vial contains both components, the declared ratio, or the stated total fill. Mixing, transfer, lyophilization, and filling introduce new opportunities for loss and segregation.
The TB-500 name adds an identity problem before the blend reaches the instrument. BPC-157 is commonly specified as a defined 15-residue peptide, although salt and terminal details still need confirmation. TB-500 is a trade name used inconsistently for full-length thymosin beta 4, a fragment, or an incompletely disclosed derivative. A blend specification stating only “BPC-157 5 mg + TB-500 5 mg” does not define the second analyte.
Require the complete TB-500 sequence, N- and C-terminal states, modifications, counterion, and theoretical mass. If the supplier intends full-length 43-residue thymosin beta 4, say so explicitly. Evidence for the LKKTET actin-binding motif does not establish that an undisclosed fragment is equivalent to the full sequence.
Why one HPLC percentage fails
The components may have different UV response factors. Equal peak areas do not mean equal mass. A shorter BPC-157 analyte and a longer or differently charged TB-500 material may ionize differently in MS, so MS peak intensity is not a direct blend-ratio assay either. Quantitation requires component-specific calibration with qualified references or another validated response model.
A generic gradient can also miss impurities selectively. Hydrophilic deletion fragments may elute near the solvent front. Oxidized or truncated thymosin-related material may cluster near the parent. If the method was optimized for BPC-157 alone, TB-500 can appear broad, carry over, or remain partly adsorbed. The resulting trace may still integrate to a flattering number.
Use extracted-ion chromatograms for each expected charge-state series and inspect the raw spectra. Intact mass confirms major components within its structural limits. For an ambiguous TB-500 material, sequence-resolving MS/MS or peptide mapping is more important than it is for a fully disclosed, qualified standard. Isomeric sequence and stereochemical errors can survive an intact-mass check.
Test the final container
Final-vial assay catches failures that raw-material testing cannot. Peptides can adsorb differently to the mixing vessel, sterile filter, tubing, or vial. A blend can start at the correct ratio and finish biased after one component is lost at an interface. Fill-volume variation and cake heterogeneity add further error.
Sample several positions across the filling run—beginning, middle, and end—using a predefined plan. Measure each component and total content. A composite sample can hide vial-to-vial variation. If the powder was dry blended before dissolution, segregation risk is higher and the sampling plan must reflect it.
Blend COA release checklist
- Exact sequence and modification record for both components, especially the material sold as TB-500.
- Separate LC-MS identity result for BPC-157 and the disclosed TB-500/thymosin construct.
- Component-specific related-substance review across the full chromatographic window.
- Calibrated quantitative assay for each peptide and a justified blend-ratio acceptance range.
- Final-container fill, water, counterion, residual solvent, and reconstitution-recovery information.
- System suitability, individual reference injections, blank, and post-blend carryover check.
One supplier pattern is to show a BPC-157 chromatogram with two peaks labeled “BPC” and “TB,” without any reference injection or spectral assignment. Another merges two old raw-material reports under a new blend batch number. Match acquisition dates and sample IDs to the filling record. A final-vial test should occur after the blend exists.
Sample preparation can bias the answer
Choose a diluent that recovers both components. A clear solution does not prove complete recovery; one peptide may adsorb while the other remains in solution. Compare low-binding containers and check concentration linearity. Avoid filtering unless filter recovery is validated for both analytes. If centrifugation is used, analyze or account for the pellet during investigation.
Define autosampler stability. A ratio that drifts during the run may reflect component-specific loss or degradation. Bracket the sequence with mixed standards and reinject an early preparation near the end. Strong needle wash and blank placement are particularly important when the TB-500 definition corresponds to a longer, more surface-active peptide.
Store the lyophilized blend sealed, dry, and light-protected at conditions supported by the final formulation’s data. Stability results from the two separate raw materials do not establish blend stability. Interactions between components, shared excipients, residual moisture, and pH after dissolution can change the profile.
The literature for BPC-157 and thymosin beta 4 remains largely preclinical and molecule-specific. It cannot resolve an ambiguous trade name or validate a commercial blend. Procurement should settle chemical identity first, then assay the final vial.
Peptides Archive can review a proposed RUO blend specification or help define the minimum component-specific COA fields before purchase. This article addresses identity, quality control, and research documentation only. It does not provide combination, dosing, administration, or human-use advice.
Report ratio uncertainty honestly. If the target is 1:1 by mass, convert the calibrated results to the same reporting basis before calculating it. Water and counterion corrections can move the apparent ratio, especially when the two raw materials carry different salt loads. Replicate sample preparations are more informative than repeated injections from one vial because they include dissolution and sampling error. When a ratio fails, test retained raw materials and in-process samples before blaming the final analytical run.
Keep the two reference solutions separate until the mixed-system check. This makes it possible to identify coelution, suppression, or a contaminated standard. A reference blend prepared from the same commercial vial under test is circular evidence and should never serve as the sole calibrator.
Primary records and verification routes
Use the primary paper, current regulator record, or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not evidence itself.